

Supplementary material - Do commonly administered drugs inadvertently modify the progression of spinal cord injury? A systematic review

Table of Contents

<i>Figures</i>	2
Figure S1	2
Figure S2	3
<i>Tables</i>	4
Table S1.....	4
Table S2.....	8
Table S3.....	16
Table S4.....	17
Table S5.....	20
Table S6.....	21
Table S7.....	22

Figures




Figure S1

Publication trends over time. A. General overview of the number of experiments included per year of publication. B. Details of repartition of species used in animal models over time. C. Details of repartition of sex in animal models over time.




Figure S2

Details of the mixed drug effects reported for drugs studied in at least five experiments. Circle size is proportional to the number of experiments reporting the effect of interest. Circles are colored proportionally to the frequency that the effect of interest represents among all experiments studying the drug of interest.

Tables

Table S1.

List of drugs included in analysis. Shaded rows highlight drugs tested in combination.

Drug(s) tested	Number of publications
acetylcysteine	5
acetylsalicylic acid	1
albumin	3
aluminum	1
amiloride	4
amphetamine	2
atorvastatin	9
azithromycin	2
baclofen	1
botulinum toxin	1
bupivacaine	1
buspirone	2
calcitriol	2
carbidopa levodopa	1
carvedilol	2
ceftriaxone	2
ceftriaxone + acetylcysteine	1
celecoxib	1
chlorpromazine	1
citalopram	1
clonidine	1
clopidogrel	1
cypheptadine	3
dantrolene	4
dapsone	1
darbepoetin	1
dexamethasone	15
dexamethasone + estrogen	1
dexamethasone + melatonin	1
dexmedetomidine	2
diclofenac	1
epinephrine	1
epinephrine + nitroprusside	1
epoetin	4
epoietin	2
escitalopram	2
estradiol	18
estradiol + testosterone	1

estrogen	3
ethanol	2
ethanol + isoflurane	1
ethanol + ketamine + pentobarbital	1
etomidate	1
etomidate + epoietin	1
etomidate + methylprednisolone	1
ezetimibe	1
ezetimibe + simvastatin	1
fenofibrate	1
fentanyl + nitrous oxide	1
fentanyl + nitrous oxide + naloxone	1
fluoxetine	4
fluoxetine + vitamin c	1
folic acid	2
folic acid + nitrous oxide	1
gabapentin	1
glibenclamide	1
glucosamine	1
glutamine	2
heparin	2
hydralazine	1
ibuprofen	4
immune globulin	3
indomethacin	3
ketoprofen	1
levocarnitine	1
levodopa	2
lidocaine	2
liothyronine	1
lithium	8
magnesium	2
magnesium + methylprednisolone	1
magnesium chloride + polyethylene glycol	3
magnesium sulfate	5
magnesium sulfate + polyethylene glycol	2
mannitol	3
melatonin	21
meloxicam	1
metformin	5
methotrexate	3
methylprednisolone	81
methylprednisolone + acetylcysteine	1

methylprednisolone + epoietin	1
methylprednisolone + magnesium chloride + polyethylene glycol	1
methylprednisolone + magnesium sulfate	1
methylprednisolone + melatonin	1
methylprednisolone + methotrexate	1
methylprednisolone + mycophenolate	1
methylprednisolone + pregabalin	1
methylprednisolone + rosuvastatin	1
methylprednisolone sodium succinate	23
methylprednisolone sodium succinate + aminocaproic acid	1
methylprednisolone sodium succinate + dantrolene	1
methylprednisolone sodium succinate + vitamin c	1
mexiletine	2
minocycline	22
minocycline + tacrolimus	1
modafinil	1
montelukast	2
morphine	6
morphine + minocycline	1
morphine sulfate	2
mycophenolate	1
naloxone	24
naltrexone	1
naproxen	2
niacin	1
nicotine	1
nifedipine	1
nitrous oxide	1
omega 3	5
oxandrolone	1
pentobarbital	1
phenytoin	4
pioglitazone	3
plasma	1
platelets	1
polyethylene glycol	10
prednisolone	1
prednisone	1
pregabalin	2
progesterone	3
progesterone + vitamin d	1
propofol	2
selegiline	1

sevoflurane	1
simvastatin	8
sitagliptin	1
tacrolimus	8
tadalafil	1
tamoxifen	8
testosterone	2
theophylline	1
thiopental	1
thiopental + naloxone	1
topiramate	3
tramadol	1
trifluoperazine	1
ubiquinone	1
valproic acid	10
vitamin c	3
vitamin c e	1
vitamin d	2
vitamin e	2
zinc	4

Table S2.
Neurological and functional outcomes for animal studies included in the review

Category	Harmonised assessment name	Assessment name as reported in literature
locomotion	BBB	Basso Beattie Brenahan (BBB) locomotor scale
		Basso Beattie and Bresnahan (BBB) rating scale
		Basso Beattie Brenahan (BBB) locomotor scale
		Basso-Beattie-and Bresnahan (BBB) scale
		Basso-Beattie-Bresnahan (BBB) scale
		BBB
		BBB hind limb locomotor rating scale
		BBB locomotor score
		BBB locomotor scale
		BBB locomotor rating scale
		BBB locomotor scale
		BBB locomotor scale (canine)
		BBB locomotor scale (modified)
		BBB locomotor scale (mouse version adapted to local protocol)
		BBB locomotor scale (mouse version)
		BBB locomotor score
		BBB Locomotor test
		BBB locomotor test
		BBB method
		BBB rating scale
		BBB scale
		BBB score
		BBB scoring
		BBB scoring scale
		BBB scoring system
		BBB subscores
		BBB subscoring
		BBB test
		modified BBB hindlimb locomotor scale
		modified murine BBB hindlimb locomotor rating scale
		modified murine BBB hindlimb locomotor-rating scale
		modified murine BBB scale
		straight alley BBB
	BMS	Basso mouse scale
		Basso Mouse Scale (BMS)
		Basso Mouse scale (BMS)
		Basso mouse scale (BMS)
		BBB locomotor scale (mouse version adapted to local protocol)
		BMS
		BMS scale

	BMS score
beam walk test	beam walk beam walk test beam walk tests Beam walking test narrow beam crossing test narrow beam test narrow beam test narrow beam-crossing test tapered beam test tapered beam walk test
footprint analysis	foot print analysis (fine motor control) footprint analysis footprint analysis (fine motor control) footprint recording
gait analysis	2D hindlimb kinematics during weight-supported treadmill locomotion 3D kinematic data angulograms (quality and range of motion) base of support catwalk gait analysis CatWalk gait analysis Catwalk-automated quantitative gait analysis Gait analysis gait analysis (DigiGait) gait analysis with CatWalk XT 10.6 multivariate system gait recording hind limb gait kinematic analysis with the CatWalk gait analysis system kinematic profile locomotion analysis with MotoRater apparatus locomotor analysis with MotoRater apparatus toe spread index
grid walking test	grid walk test gridwalk test grid walking test grid-walking test horizontal grid walking ability to traverse wire grid horizontal grid grid footfalls grid walking
inclined plane test	angled plane score incline plane score (IPS)

	incline plane test method
	inclined plane
	inclined plane assessemnt
	inclined plane assessment
	inclined plane method
	inclined plane method of Rivlin and Tator
	inclined plane score
	inclined plane score (IPS)
	inclined plane task
	inclined plane technique
	inclined plane test
	inclined plane test (modified Rivlin's method)
	inclined plane test method
	inclined plane tests
	inclined plate test
	inclined test
	rivlin and tator's inclined plane test
	Rivlin inclined plane test
ladder walk test	45 degrees ladder walk test
	footfalls
	horizontal ladder
	horizontal ladder crossing test
	horizontal ladder task
	horizontal ladder test
	horizontal ladder test (adapted to local protocol)
	horizontal ladder walk test
	horizontal ladder walk tests
	ladder walk
	ladder walk test
	ladder walk tests
	walk on ladder
locomotor (other)	activity box
	activity box test (ABT)
	activity measures
	categorisation of walking ability (paraplegia/poor walker/walker)
	clinical grading
	clinical motor exam (Drummond and Moore)
	Drummond and Moore criteria
	Drummond and Moore motor function score
	Eugene D Means and Douglas K Anderson's motility score
	Forelimb locomotor scale
	grading of motor disturbance (Drummond and Moore scale)
	gross motor activity (activity box)

		hind limb motor function score (MFS)
		motor capacity
		motor deficit index
		motor function
		motor function scale
		motor function scale (Farooque)
		motor performance on rotarod
		neurological function (walking status)
		neurological scores (locomotor status)
		Open field test
		open field test
		porcine thoracic behavior scale
		presence/absence of hindlimb paralysis
		recovery index (mobility)
		rotarod
		rotarod locomotor function test
		spontaneous movement
		unprompted walking motor score
	swimming	swimming performance swimming test
	Tarlov scale	five-point modified Tarlov scale hind limb motor function (modified Tarlov) hind-limb motor-function according to Tarlov modified five-point scale developed by Tarlov modified Tarlov method modified Tarlov rating system modified Tarlov scale modified Tarlov scale modified Tarlov score modified Tarlov scoring system modified tarlov's grading scale modified Tarlov's motor scale motor function (modified Tarlov scale) Tarlov motor scale Tarlov scale Tarlov scoring Tarlov scoring system Tarlov's scoring system Tarlow scale
forelimb function	grip strength	grip strength meter grip strength task
	reaching or retrieval	directed forepaw reaching (DFR) grasping test (food retrieval)

		modified Montoya's staircase test
		Montoya staircase reaching
		staircase test
		vermicelli handling test
	rearing	cylinder rearing test
		cylinder test (forelimb assymetry)
		open field test (rearing)
		paw placement
		rearing
sensory and pain	mechanical reactivity	cutaneous trunci muscle reflex
		cutaneous trunci muscle (CTM) reflex
		foot withdrawal under mechanical stimuli
		girdle test
		localisation reflex
		mechanical reactivity
		mechanical reactivity (von Frey)
		mechanical sensitivity
		mechanical sensitivity (von Frey filaments)
		proprioception
		proprioceptive placing response
		response to mechanical stimuli
		sensory function (paw withdrawal)
		sensory function (von Frey filaments)
		sensory testing (forelimb withdrawal under mechanical stimulation)
		tactile capacity
		tactile reactivity
		tactile reactivity (girdle test)
		tactile sensory test with Von Frey filaments
		tape sensing and removal test
		touch-evoked agitation
		vocal/sensory score
		vocalization threshold to mechanical pressure
		Von Frey test
		von Frey test
		Von Frey testing
	other reflexes	physiological reflexes
		test of hindlimb reflexes
pain		gross neurologic examination
		hindpaw pinprick sensory threshold test
		hindpaw pinprick sensory treshold test
		hindpaw withdrawal threshold for mechanical allodynia
		hindpaw withdrawal treshold for mechanical allodynia
		mechanical allodynia

		<p>mechanical allodynia testing</p> <p>painful stimulus by pinching of rat tail</p> <p>paraplegia status (tail pinch)</p> <p>pinprick</p> <p>purposeful response to paw pinch</p> <p>Rat Grimace Scale</p> <p>response to noxious stimulation</p> <p>sensitivity to pain</p> <p>Von Frey test of mechanical allodynia/hyperalgesia</p>
	thermal reactivity	<p>acetone drop test</p> <p>Hargreave's test</p> <p>hot-water test</p> <p>neuropathic pain evaluation [acetone drop test and thermal hyperalgesia]</p> <p>nociceptive reactivity (thermal shock threshold tested through tail-flick test)</p> <p>nociceptive reactivity (thermal)</p> <p>sensory blockade (heat)</p> <p>sensory function (hot plate/cold stimulation)</p> <p>tail flick test</p> <p>tail-flick test</p> <p>thermal hyperalgesia</p> <p>thermal reactivity (standard hot-plate test/cold stimulation)</p> <p>thermal reactivity</p> <p>thermal sensitivity</p> <p>Thermal Sensitivity</p> <p>thermal sensitivity (tail flick)</p>
	toe spread test	<p>toe spread test</p> <p>toe-spread test</p> <p>toe spread tests</p> <p>toe spread</p> <p>toe spread reflex</p>
electrophysiology	electrophysiology (other)	<p>activity in hemidiaphragm and phrenic nerve ipsilateral to hemisection</p> <p>assessment of H-reflex</p> <p>compound action potential (CAP) recording</p> <p>compound action potentials</p> <p>EMG recordings</p> <p>frequency dependent depression (FDD) of H-reflex</p> <p>H-reflex analysis</p> <p>sciatic nerve stimulation</p>
	motor evoked potentials	<p>corticomotor evoked potentials</p> <p>corticomotor evoked potentials (CMEPs)</p> <p>evoked muscle responses (EMR)</p> <p>evoked potential test (MEP)</p> <p>motor evoked potential</p>

		motor evoked potential (MEP)
		motor evoked potentials
		motor evoked potentials (MEP)
		motor evoked potentials recording
		Motor-evoked potential (MEP)
		motor-evoked potential (MEPs)
		motor-evoked potentials (MEPs)
		rubrospinal motor evoked potentials (rMEP)
		spinal motor-evoked potentials (sMEPs)
	somatosensory evoked potentials	cortical somatosensory evoked potentials cortico somatosensory evoked potentials (CSEP) evoked potentials measured SEPs somatosensory evoked potential (SEP) somatosensory evoked potential (SEPs) somatosensory evoked potential (SSEP) somatosensory evoked potentials somatosensory evoked potentials (SEP) somatosensory evoked potentials (SEPs) somatosensory evoked potentials (SSEP) somatosensory evoked potentials (SSEPs) somatosensory evoked responses (SER) somatosensory-evoked potential (SEPs) somatosensory-evoked potentials (SEPs) somatosensory evoked potentials (SSEP) SSEP SSEPs
	spinal cord evoked potentials	spinal cord evoked potential recording spinal cord evoked potentials spinal cord evoked potentials (SCEPs) spinal evoked potentials (SEP)
other	composite scores	motor sensory deficit index (MSDI) neurologic scores (motor and sensory deficit) sensory and motor evaluations (paraplegia status)
	Gale scale	combined behavioral score (Gale scale/CBS) functional deficits scoring Gale scale gale scale modified Gale scale motor function scale (modified Gale) motor function scale according to Gale et al. (1985) motor function score (modified Gale) overall hindlimb impairment (modified CBS)

hindfoot bar grab test	hindfoot bar grab test hindfoot bar grab tests
micturition	bladder function micturition (voiding behaviour)
spinal cord blood flow	spinal cord blood flow spinal cord blood flow (SCBF)

Table S3.
Neurological and functional outcomes for human studies included in the review

Category	Assessment name reported	Assessment
neurological	neurological (motor and sensory)	marked recovery (combination of improvement in AIS grade and walking function) pinprick, light touch, motor function scale ASIA motor and sensory scores ASIA scale: motor and sensory composites ASIA motor score, ASIA sensory score motor score; light touch (LT) and pin prick (PP) scores
	neurological (motor)	ASIA motor score ASIA Motor score ISNCSCI motor score strength discharge motor score
	neurological (other)	improvement to level of injury (change in segment to more caudal location)
	injury severity	marked recovery (combination of improvement in AIS grade and walking function) improvement in ASIA scale ASIA impairment score and grade ASIA grade
functional	functional (general)	Spinal Cord Independence Measure Functional Independence Measure London Handicap scale Short Form 36 Questionnaire FIM discharge score
	functional (mobility)	FIM motor score
	functional (mobility and general)	Walking Index for SCI II (WISCI II), Spinal Cord Independence Measure II (SCIM II)
	functional (mobility and spasticity)	overground walking performance; treadmill walking performance spastic reflexes (modified Ashworth scale); walking function
electrophysiology		EMG

Table S4.
Variables extracted from studies included for analysis

Variable extracted		Details
General information	Person in charge	Person in charge of the data extraction
	Authors	First author et al
	Year	Year of publication
	Title	Full title
	DOI or PMID	Unique identifier
	Language	Language of the main text
Inclusion/exclusion	Included/excluded	Included or excluded
	Reason for exclusion	Primary reason of exclusion
	Reason for exclusion	Reason of exclusion if primary reason of exclusion is "out of scope"
	Reason for exclusion (description)	Description of the reason of exclusion
Classification	Data collection	Prospective or retrospective (human studies only)
	Analysis	Prospective or retrospective (human studies only)
Study population	Species	Species studied among humans, mice, rats, dogs, cats, fish, lampreys, sheep, rabbits, guinea pigs, others
	Species information	Information about subspecies used
	Count, n	Total number of subjects reported
	Count, n control group	Number of subjects in control group (included in analysis)
	Count, n died in control group	Number of subjects assigned to control group not included in analysis due to premature death
	Count, n excluded in control group	Number of subjects assigned to control group not included in analysis for other reasons
	Count, n treatment group	Number of subjects in treatment group (included in analysis)
	Count, n died in treatment group	Number of subjects assigned to treatment group not included in analysis due to premature death
	Count, n excluded in treatment group	Number of subjects assigned to treatment group not included in analysis for other reasons
	Comment on counts	Details on counts, especially when total control + total treatment do not add to total n
	Sex (n, ratio, percentage)	Information about sex of subjects as reported in the publication
	Sex	One option among female, male, mixed and not reported
	Sex (% , male)	% male included in the study
	Age [days, months, years]	Information about age of subjects as reported in the publication
	Age (mean)	Mean age (when applicable)
	Age (SD)	SD age (when applicable)
	Age (min)	Minimum age (when age range reported)
	Age (max)	Maximum age (when age range reported)
	Age (units)	Age units used among days, weeks, months and years
	Age (comments)	Comment on age information, one option among not reported, adult, young, for publication not reporting precise age included
	Weight [g, kg, pounds]	Information about weight of subjects as reported in the publication
	Weight (mean)	Mean weight (when applicable)
	Weight (SD)	SD weight (when applicable)
	Weight (min)	Minimum weight (when weight range reported)

	Weight (max)	Maximum weight (when weight range reported)
	Weight (unit)	Weight units among g, kg, pounds
	Weight (comments)	Comment on weight information (e.g., not reported)
	Injury characteristics (level, severity)	Information about injury characteristics included level and severity as reported in the publication
	Injury level	Level of injury (unique level or range for animal studies, number of subject per level or category for human studies)
	Injury severity	Injury severity among moderate, mild, severe, complete, incomplete, paraplegia, tetraplegia, not reported, mixed and moderate-severe
	Injury mechanism	Injury mechanism among contusion, compression, distraction, dislocation, transection, ischemia, trauma and others. Note this classification mainly applies for animal models, injury mechanism reported may differ in human studies
	Injury mechanism (details)	Details on injury mechanisms (e.g., height and weight used in contusion injuries, time before reperfusion in ischemic injuries etc)
	Duration of SCI	Duration of SCI before euthanasia (animals) or duration of SCI before inclusion in study (human)
Drug information	Drug(s)	Drug(s) studied in the publication
	Drug name harmonized	Drug name harmonized based on [Bourguignon et al., 2022]
	MP used as main drug?	Yes or no, for publication investigation methylprednisolone and methylprednisolone sodium succinate only (assess if the drug was the main drug of interest or used as positive control)
	Dose (absolute dose or mg/kg)	Dose given
	Time (minutes pre-injury, minutes post-injury)	Timing of start of treatment compared to injury
	Duration of treatment	Duration of treatment
	Timing (e.g., BID, PID)	Frequency of treatment
	Route	Route used for drug administration
	Route (comment when multiple)	Comments on the route used
Neurological and functional assessment	What was assessed? (e.g., neurological, functional recovery, spasticity, walking function, electrophysiology)	Type of neurological/functional assessment (broad categories)
	Name/type of assesment	Neurological/functional assessments as named in the publication
	Name of assessment harmonised	Neurological/functional assessments' names harmonised as described in Table S3
	Details on assesment	Details on assessments as described in the publications
	Timing of assesment	Time of assessment with respect to the injury
	Assessment on day 28 (yes/no)	Whether subjects were assessed at day 28 after injury (applies to experiments testing methylprednisolone and methylprednisolone sodium succinate only)
	Was observer blinded?	Options among no, yes and not reported
	Drug effect on functional assessment	Options qualifying effects among positive, negative, no effect, mixed (assessment), mixed (dosage), mixed (timing), mixed (regime), no stats, mixed (stats/no stats), mixed (assessment) + mixed (timing), not reported, mixed (dosage) + mixed (timing), mixed (dosage) + mixed (assessment), mixed (dosage) + mixed (regime), mixed (assessment) + mixed (regime)
	Drug effect on functional assessment (details)	Details on the effects reported allowing to categorize the effects in the previous column
Neuroanatomical assessments	What was assessed? (e.g., histological measures, cavity measures, ect)	Type of histological assessment (broad categories)
	Name/type of assesment	Histology assessments as named in the publication
	Timing of assesment	Time of assessment with respect to the injury
	Was observer blinded?	Options among no, yes and not reported
	Drug effect on neuroanatomical assessment	Options qualifying effects among positive, negative, no effect, mixed (assessment), mixed (dosage), mixed (timing), mixed (timing of assessment), no stats, mixed (stats/no stats), mixed (assessment) + mixed (dosage), not reported, and mixed (assessment) + mixed (timing)
	Drug effect on neuroanatomical assessment (details)	Details on the effects reported allowing to categorize the effects in the previous column

Conclusions and others	Drugs given to treat infections/pain ect.	Other drugs given to subjects according to the study protocol (e.g., pain relief plan, infection treatment or prophylaxis, anesthesia)
	Conclusion of study	Conclusions as reported in the publication
	Limitations	Limitations mentioned in the publication
	Remarks/Comments	Personal remark or comments following extractions
	Combination of drugs tested	Options among no, yes (drug of interest + drug of interest), and yes (drug of interest + drug not of interest)
	Contradictions present in the results	Yes or no, flags contradictions between text and figures presented in a given manuscript

Table S5.

Details on the bias classification for animal experiments.

Domain of bias	Classified as “unclear risk of bias”	Classified “high risk of bias”
Dose	No precise dose reported, including “high dose”	Not reported
Species	Subspecies not reported	Not reported
Route	-	Not reported
Level of injury	No precise level or range reported, including “cervical”, “mid-thoracic”, “thoracic”, “lumbar-sacral”	Not reported
Treatment time	-	Not reported
Results	Mixed results due to lack of statistics reported, including "mixed (stats/no stats)", "mixed effects (assessment) + mixed (stats/no stats)", "no stats"	Not reported
Sample size	Sample size reported as range or bounded	Not reported
Sex	Mixed population (male/female) with ratio not reported	Not reported
Blinding	Not reported	No blinding applied
Age	Reported as “adult”, “young” with no precise age reported	Not reported

Table S6.

Reported sample sizes by species in animal studies. “Other” include Yucatan miniature pigs (n=2) yellow eel *Anguilla anguilla* L. (n=1) SD: standard deviation; Q1: first quartile; Q3: third quartile

Species	Mean	SD	Median	Q1	Q3
cats	26.53	16.50	24.00	16.50	31.00
dogs	33.43	25.13	26.00	22.00	32.00
guinea pig	21.00	7.55	20.00	17.00	24.50
mice	120.62	83.33	96.00	50.25	176.50
other	31.33	16.17	22.00	22.00	36.00
rabbit	69.36	50.57	47.00	28.50	133.00
rats	61.60	46.71	48.00	32.00	79.50

Table S7.
Bias assessment by animal experiment

Experiment	Domain of bias										Total bias score
	Species	Sample size	Sex	Age	Level of injury	Dose	Treatment time	Route	Results	Blinding	
Pinzon et al. (2008, minocycline)	0	0	0	1	0	0	0	0	0	0	1
Sharp et al (2013, ibuprofen)	0	0	0	0	0	0	0	0	0	0	0
Liu et al (2015, omega 3)	0	1	0	1	0	0	0	0	0	0	2
Bimbova et al (2018, atorvastatin)	0	0	0	1	0	0	0	0	0	1	2
Liu et al (2017, omega 3)	0	1	0	1	0	0	0	0	0	0	2
Yang et al (2016, niacin)	0	0	0	1	0	0	0	0	0	0	1
Jiang et al (2004, methylprednisolone)	0	1	0	1	0	0	0	0	0	0	2
Halt et al (1992, ethanol + isoflurane)	1	0	2	2	0	0	0	0	0	0	5
Halt et al (1992, ethanol + ketamine + pentobarbital)	1	0	2	2	0	0	0	0	0	0	5
Durham-Lee et al (2011, amiloride)	0	0	0	1	0	0	0	0	0	1	2
Imai et al (2018, amiloride)	0	1	0	0	0	0	0	0	0	1	2
Krisa et al (2012, amphetamine)	0	0	0	1	0	0	0	0	0	0	1
Hook et al (2011, morphine)	0	0	0	0	0	0	0	0	0	0	0
Gao et al (2014, methylprednisolone)	0	0	0	1	0	0	0	0	0	1	2
Baiyila et al (2018, methylprednisolone)	0	0	2	1	0	0	2	0	0	1	6
Bilginer et al (2009, methylprednisolone)	0	0	0	1	0	0	0	0	0	1	2
Bilginer et al (2009, mycophenolate)	0	0	0	1	0	0	0	0	0	1	2
Bilginer et al (2009, methylprednisolone + mycophenolate)	0	0	0	1	0	0	0	0	0	1	2
Hong et al (2020, vitamin c)	0	1	0	0	0	0	0	0	0	0	1
Martins et al (2018, dantrolene)	0	0	0	0	0	0	0	0	0	0	0
Gao et al (2016, atorvastatin)	0	0	0	0	0	0	0	0	0	1	1
Déry et al (2009, atorvastatin)	0	0	0	1	0	0	0	0	0	1	2
Yeng et al (2016, estradiol)	0	0	0	1	0	0	0	0	0	0	1
Genovese et al (2005, melatonin)	0	0	0	2	0	0	0	2	0	1	5
Pannu et al (2005, atorvastatin)	0	1	0	2	0	0	0	0	0	0	3
Nash et al (2002, methylprednisolone)	0	0	2	1	0	0	0	0	0	0	3
Zhang et al (2015, azithromycin)	0	1	0	0	0	0	0	0	0	0	1
Faden et al (1981, naloxone)	1	0	0	1	0	0	0	0	0	0	2
Giulian et al (1990, dexamethasone)	0	1	2	2	1	0	0	0	0	1	7
Salzman et al (1991, cyproheptadine)	0	0	0	2	0	0	0	0	0	0	2
Siriphorn et al (2012, estradiol)	0	0	0	1	0	0	0	0	0	0	1
Mohammadshirazi et al (2019, lithium)	0	0	0	1	0	0	0	0	0	1	2
Rabchevsky et al (2002, methylprednisolone sodium succinate)	0	0	0	1	0	0	0	0	0	0	1
Borgens et al (2001, polyethylene glycol)	1	0	2	1	1	0	0	0	0	1	6
Ditor et al (2007, polyethylene glycol)	0	0	0	2	0	0	0	0	0	0	2
Ditor et al (2007, magnesium sulfate)	0	0	0	2	0	0	0	0	0	0	2
Ditor et al (2007, magnesium sulfate + polyethylene glycol)	0	0	0	2	0	0	0	0	0	0	2
Liu et al (2015, carvedilol)	0	0	0	0	0	0	0	0	0	0	0

Diaz-Ruiz et al (2011, dapsone)	0	0	0	1	0	0	0	0	0	0	1
Krityakiarana et al (2016, melatonin)	1	0	0	0	0	0	0	0	0	1	2
Vanicky et al (2002, methylprednisolone sodium succinate)	0	0	0	2	0	0	0	0	0	0	2
Behrmann et al (1994, methylprednisolone sodium succinate)	0	0	0	2	0	0	0	0	0	0	2
Sadanaga et al (1989, chlorpromazine)	0	1	0	2	0	0	0	0	0	0	3
Gueye et al (2015, vitamin d)	0	0	0	0	0	0	0	0	0	1	1
Guth et al (1994, indomethacin)	0	0	0	2	0	0	2	0	2	0	6
Nazemi et al (2020, minocycline)	0	0	0	1	0	0	0	0	0	1	2
Lopez et al (2004, bupivacaine)	0	0	0	0	0	0	0	0	0	0	0
Namjoo et al (2018, estradiol) - rats - 10.1007/s11011-018-0220-8	0	0	0	1	0	0	0	0	0	0	1
Çavus et al (2014, methylprednisolone)	0	0	0	0	0	0	0	0	0	0	0
Çavus et al (2014, acetylcysteine)	0	0	0	0	0	0	0	0	0	0	0
Çavus et al (2014, methylprednisolone + acetylcysteine)	0	0	0	0	0	0	0	0	0	0	0
Kang et al (2017, estradiol)	0	0	0	0	2	0	0	0	0	1	3
Baltin et al (2021, methylprednisolone sodium succinate)	0	0	0	2	0	0	0	0	0	1	3
Chen et al (2018, methylprednisolone)	0	1	0	1	0	0	0	0	0	1	3
Caliskan et al (2016, etomidate)	0	0	0	1	0	0	0	0	0	0	1
Caliskan et al (2016, epoietin)	0	0	0	1	0	0	0	0	0	0	1
Caliskan et al (2016, etomidate + epoietin)	0	0	0	1	0	0	0	0	0	0	1
Cayli et al (2004, methylprednisolone)	0	0	0	1	0	0	0	0	0	1	2
Cayli et al (2004, melatonin)	0	0	0	1	0	0	0	0	0	1	2
Cayli et al (2004, methylprednisolone + melatonin)	0	0	0	1	0	0	0	0	0	1	2
Cayli et al (2004, ethanol)	0	0	0	1	0	0	0	0	0	1	2
Cetin et al (2006, methylprednisolone)	0	0	2	2	0	0	0	0	0	1	5
Cetin et al (2006, epoietin)	0	0	2	2	0	0	0	0	0	1	5
Cetin et al (2006, methylprednisolone + epoietin)	0	0	2	2	0	0	0	0	0	1	5
Ha et al. (2008, pregabalin)	0	0	0	1	0	0	0	0	0	1	2
Ha et al. (2008, methylprednisolone)	0	0	0	1	0	0	0	0	2	1	4
Ha et al. (2008, minocycline)	0	0	0	1	0	0	0	0	2	1	4
Aslan et al (2009, dexmedetomidine)	0	0	1	2	0	0	0	0	2	0	5
Aslan et al (2009, dantrolene)	0	0	1	2	0	0	2	0	0	0	5
Colón et al (2018, tamoxifen)	0	1	0	0	0	0	0	0	0	0	1
Xu et al (2009, dexamethasone)	0	0	0	1	0	0	0	0	0	1	2
Saganová et al (2009, tacrolimus)	0	0	0	2	0	0	0	0	0	1	3
Fabela-Sánchez et al (2018, albumin)	0	0	0	2	0	0	0	0	0	0	2
Darvishi et al (2014, valproic acid)	0	1	0	2	0	0	0	0	1	1	5
Torres et al (2018, dantrolene)	0	0	0	0	0	0	0	0	0	1	1
Guo et al (2018, metformin)	0	0	0	2	0	0	2	0	0	0	4
Chio et al (2021, immune globulin)	0	0	0	1	0	0	0	0	0	0	1
Kopper et al (2019, azithromycin)	0	0	0	0	0	0	0	0	0	0	0
Afshary et al. (2020, minocycline)	0	0	0	2	0	0	0	0	0	0	2
Zhang et al. (2017, metformin) - rats - 10.1007/s12035-016-9895-1	0	1	0	1	0	0	0	0	0	0	2
Liu et al. (2017, lithium)	0	1	0	0	0	0	0	0	0	1	2
Jin et al. (2021, buspirone)	0	0	0	0	0	0	0	0	0	0	0
Jin et al. (2021, fluoxetine)	0	0	0	0	0	0	0	0	0	0	0
Brandoli et al. (2001, dexamethasone)	0	0	0	2	0	0	0	0	0	0	2

Faden et al (1984, naloxone)	0	0	2	2	2	0	0	0	0	0	6
Hashimoto et al. (1991, naloxone)	0	0	0	2		0	0	0	0	0	2
Winkler et al (1994, naloxone)	0	0	0	2	0	0	0	0	0	1	3
Faden et al (1983, naloxone) - cats	0	0	0	2	0	0	0	0	0	0	2
Faden et al (1983, naloxone) - rats	0	0	0	2	0	0	0	0	1	0	3
Faden et al (1983, naloxone) - rabbit	0	0	2	2	1	0	0	0	1	0	6
Chen et al. (2020, ezetimibe)	0	0	0	1	0	0	0	0	0	0	1
Oslau et al (2014, selegiline)	0	1	0	2	0	0	0	0	1	1	5
Salem et al. (2017, methylprednisolone sodium succinate)	0	0	0	1	0	0	0	0	0	0	1
Salem et al. (2017, vitamin c)	0	0	0	1	0	0	0	0	0	0	1
Salem et al. (2017, methylprednisolone sodium succinate + vitamin c)	0	0	0	1	0	0	0	0	0	0	1
Abdanipour et al. (2012, valproic acid)	0	0	0	2	0	0	0	0	0	0	2
Teixeira et al. (2018, methylprednisolone)	0	0	0	0	0	0	0	0	0	0	0
Tong et al. (2018, lithium)	0	1	0	1	2	0	0	0	0	1	5
Karatas et al. (2015, carvedilol)	0	0	2	2	0	2	2	2	0	1	1
Papa et al. (2016, minocycline)	0	1	2	2	0	0	0	0	0	0	5
Pourheydar et al. (2018, ubiquinone)	0	0	0	2	0	0	0	0	0	1	3
Pourheydar et al. (2018, vitamin c)	0	0	0	2	0	0	0	0	0	1	3
Wang et al. (2017, minocycline)	0	0	0	2	0	0	0	0	0	0	2
Wang et al. (2019, minocycline)	0	0	0	1	0	0	0	0	0	1	2
Khoshsirat et al. (2018, methylprednisolone)	0	0	0	1	0	0	2	2	0	0	5
Fee et al. (2007, progesterone)	0	0	0	0	0	0	0	2	0	0	2
Ritz et al. (2008, estradiol)	0	0	0	1	0	0	0	0	0	0	1
Means et al. (1981, methylprednisolone sodium succinate)	0	0	0	2	0	0	0	0	0	0	2
Holtz et al. (1990, methylprednisolone)	0	0	0	2	0	0	0	0	1	1	4
Korkmaz et al. (2015, montelukast)	0	0	0	2	1	0	0	2	0	0	5
Haghighi et al. (1987, naloxone)	0	0	2	1	0	0	0	0	0	1	4
Arias (1985, naloxone)	0	0	0	2	0	0	0	0	0	1	3
Ross et al. (1993, methylprednisolone)	0	0	0	2	0	0	0	0	0	0	2
Gerber et al. (1980, phenytoin)	0	0	2	2	0	0	0	0	0	0	4
Gerber et al. (1980, dexamethasone)	0	0	2	2	0	0	0	0	0	0	4
Silva et al. (2008, prednisone)	0	0	0	0	0	0	0	0	0	1	1
Pan et al. (2006, tacrolimus)	0	0	0	1	0	0	0	0	0	0	1
Liu et al. (2017, methylprednisolone)	0	0	0	2	0	0	0	0	0	1	3
Liu et al. (2017, methotrexate)	0	0	0	2	0	0	2	0	0	1	5
Liu et al. (2017, methylprednisolone + methotrexate)	0	0	0	2	0	0	0	0	0	1	3
Ahmad et al. (2016, minocycline)	0	0	0	1	0	0	0	0	0	0	1
Ahmad et al. (2016, tacrolimus)	0	0	0	1	0	0	0	0	0	0	1
Ahmad et al. (2016, minocycline + tacrolimus)	0	0	0	1	0	0	0	0	0	0	1
Meng et al. (2011, methylprednisolone)	0	1	2	1	0	0	0	0	1	0	5
Shen et al. (2019, levocarnitine)	0	0	0	0	0	0	0	0	0	1	1
Cristante et al. (2013, fluoxetine)	0	0	0	0	0	0	2	0	1	0	3
Zhou et al. (2016, calcitriol)	0	0	0	1	0	0	0	0	0	0	1
Nantwi et al. (1998, theophylline)	1	0	0	1	0	0	0	0	1	1	4
Genovese et al. (2007, dexamethasone) - mice - 10.1111/j.1600-079X.2007.00454.x	1	0	2	2	0	0	0	0	0	1	6
Genovese et al. (2007, melatonin)	1	0	2	2	0	0	0	0	0	1	6

Genovese et al. (2007, dexamethasone + melatonin)	1	0	2	2	0	0	0	0	0	1	6
Farsi et al. (2015, methylprednisolone)	1	0	0	1	0	0	0	0	0	0	2
Farsi et al. (2015, magnesium sulfate)	1	0	0	1	0	0	0	0	0	0	2
Farsi et al. (2015, methylprednisolone + magnesium sulfate)	1	0	0	1	0	0	0	0	0	0	2
Yin et al. (2013, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Lu et al. (2016, methylprednisolone)	0	0	0	0	0	0	0	0	0	0	0
Li et al. (2016, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Hou et al. (2015, celecoxib)	0	0	0	0	0	0	2	0	0	1	3
Qinxuan et al. (2020, dexamethasone + estrogen)	0	0	0	0	0	0	0	0	0	0	0
Qinxuan et al. (2020, dexamethasone)	0	0	0	0	0	0	0	0	0	0	0
Letaif et al. (2015, estradiol)	0	0	0	0	0	0	0	0	0	0	0
Hains et al. (2004, phenytoin)	0	0	0	1	0	0	0	0	0	1	2
Mann et al. (2008, epoetin)	0	0	0	2	0	0	0	0	0	0	2
Mann et al. (2008, darbepoetin)	0	0	0	2	0	0	0	0	0	0	2
Liao et al. (2014, methylprednisolone)	0	0	1	1	0	0	0	0	0	1	3
Li et al. (2019, methylprednisolone)	0	0	0	0	0	0	2	2	0	1	5
Wu et al. (2019, methylprednisolone)	0	0	0	1	0	0	2	0	0	0	3
Rong et al. (2018, methotrexate)	0	0	0	0	0	0	2	0	0	1	3
Wong et al. (2012, amphetamine)	0	0	0	0	0	0	0	0	0	0	0
Lima et al. (2020, citalopram)	0	0	0	0	0	0	0	0	0	0	0
Li et al. (2014, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Chen et al. (2014, vitamin c e)	0	0	0	1	0	0	2	0	0	0	3
Akdemir et al. (1993, methylprednisolone)	0	0	0	2	0	0	0	0	0	0	2
Genovese et al. (2008, montelukast)	0	0	0	1	0	0	0	0	0	1	2
Chen et al. (2018, plasma)	0	1	0	0	0	2	0	0	0	0	3
Chen et al. (2018, platelets)	0	1	0	0	0	0	0	0	0	0	1
Kim et al. (2004, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Mbori et al. (2016, methylprednisolone)	0	0	0	0	0	0	0	0	0	0	0
Wiseman et al. (2009, methylprednisolone)	0	0	0	1	0	0	0	0	1	0	2
Wiseman et al. (2009, magnesium)	0	0	0	1	0	0	0	0	0	0	1
Wiseman et al. (2009, magnesium + methylprednisolone)	0	0	0	1	0	0	0	0	1	0	2
Ates et al. (2007, mexiletine)	0	0	0	1	0	0	0	0	1	1	3
Ates et al. (2007, phenytoin)	0	0	0	1	0	0	0	0	1	1	3
Serarslan et al. (2010, methylprednisolone)	0	0	0	2	0	0	0	0	0	1	3
Serarslan et al. (2010, tadalafil)	0	0	0	2	0	0	0	0	0	1	3
Hara et al. (2000, methylprednisolone sodium succinate)	0	0	0	2	0	0	0	0	0	0	2
Zendedel et al. (2018, estradiol)	0	1	0	0	0	0	0	0	0	0	1
Braughler et al. (1987, methylprednisolone sodium succinate)	0	0	2	1	0	0	0	0	0	0	3
Robertson et al. (1986, thiopental)	0	0	2	2	1	0	0	0	0	1	6
Robertson et al. (1986, magnesium sulfate)	0	0	2	2	1	0	0	0	0	1	6
Robertson et al. (1986, lidocaine)	0	0	2	2	1	0	0	0	0	1	6
Robertson et al. (1986, naloxone)	0	0	2	2	1	0	0	0	0	1	6
Robertson et al. (1986, thiopental + naloxone)	0	0	2	2	1	0	0	0	0	1	6
Kobrine et al. (1984, lidocaine)	1	0	2	1	0	0	0	0	1	1	6
Hallenbeck et al. (1983, naloxone)	0	0	2	2	0	0	0	0	0	0	4
Watanabe et al. (2012, minocycline)	0	0	2	2	1	0	0	0	0	0	5

Yücel et al. (2006, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Gürkan et al. (2020, methylprednisolone)	0	0	0	2	0	0	0	0	1	1	4
Schwartz et al. (2001, phenytoin)	0	0	0	1	0	0	0	0	0	1	2
Tator et al. (1983, liothyronine)	0	0	0	2	0	0	2	0	0	0	4
Young et al. (1982, methylprednisolone sodium succinate)	1	0	2	1	0	0	0	0	1	1	6
Saganova et al. (2008, minocycline)	0	0	0	2	0	0	0	0	0	1	3
Rivlin et al. (1979, epinephrine)	0	0	0	2	0	0	0	0	0	0	2
Rivlin et al. (1979, epinephrine + nitroprusside)	0	0	0	2	0	0	0	0	0	0	2
Zhang et al. (2020, methylprednisolone)	0	0	0	0	0	0	2	0	0	0	2
Zhang et al. (2020, metformin)	0	0	0	0	0	0	2	0	0	0	2
Genovese et al. (2007, dexamethasone) - mice - 10.1016/j.neuroscience.2007.06.059	0	0	0	1	0	0	0	0	0	1	2
Wu et al. (2017, sevoflurane)	0	1	0	1	0	0	0	0	0	1	3
Lee et al. (2016, fluoxetine + vitamin c)	0	1	0	1	0	0	0	0	0	0	2
de Figueiredo et al. (2018, tramadol)	0	0	0	0	0	0	2	0	0	0	2
Vasconcelos et al. (2016, magnesium chloride + polyethylene glycol)	0	0	0	0	0	0	0	0	0	0	0
Miranpuri et al. (2017, folic acid)	0	1	0	1	0	0	0	0	0	0	2
Gül et al. (2005, methylprednisolone)	0	0	2	2	0	0	0	0	1	1	6
Gül et al. (2005, melatonin)	0	0	2	2	0	0	0	0	1	1	6
Fu et al. (2007, naproxen)	0	0	0	2	0	0	0	0	0	0	2
Fu et al. (2007, ibuprofen)	0	0	0	2	0	0	0	0	0	0	2
Cheng et al. (2016, estradiol)	0	0	0	2	0	0	2	0	0	0	4
Hu et al. (2012, estradiol)	0	1	0	2	0	0	0	0	0	0	3
Sun et al. (2020, gabapentin)	0	1	1	0	0	0	0	0	0	0	2
McCreedy et al. (2018, diclofenac)	0	1	0	0	0	0	0	0	0	0	1
Tajkey et al. (2015, ceftriaxone)	0	0	0	0	2	0	2	0	0	1	5
Zheng et al. (2011, heparin)	0	0	0	1	0	0	0	0	0	1	2
Nguyen et al. (2012, immune globulin)	0	0	0	2	0	0	0	0	0	0	2
Ueno et al. (2011, minocycline)	0	0	2	0	0	0	0	0	0	0	2
Wang et al. (2009, ibuprofen) - rats	0	0	0	0	0	0	0	0	0	0	0
Wang et al. (2009, naproxen)	0	0	0	0	0	0	0	0	0	0	0
Wang et al. (2009, ibuprofen) - mice	0	0	0	0	0	0	0	0	0	0	0
Ozkunt et al. (2017, methylprednisolone)	0	0	0	1	0	0	0	0	1	0	2
Ozkunt et al. (2017, epoetin)	0	0	0	1	0	0	0	0	1	0	2
Zakeri et al. (2014, lithium)	0	1	0	2	0	0	0	0	0	0	3
Teng et al. (2004, minocycline)	0	1	0	2	0	0	0	0	0	0	3
Wu et al. (2010, methylprednisolone)	0	2	0	0	0	0	0	0	0	0	2
Huang et al. (2009, epoetin)	0	0	0	2	0	0	0	0	0	1	3
Lee et al. (2003, minocycline)	0	1	0	2	0	0	0	0	0	0	3
Lin et al. (2016, estradiol)	0	0	0	1	0	1	0	0	0	0	2
Faden et al. (1981, naloxone)	1	0	2	1	0	0	0	0	0	0	4
Holtz et al. (1991, methylprednisolone)	0	0	0	2	0	0	0	2	0	1	5
Gorio et al. (2007, methylprednisolone sodium succinate)	0	1	2	1	0	0	0	0	0	0	4
Ravikumar et al. (2005, nicotine)	0	0	0	0	0	0	0	0	0	0	0
Know et al. (2009, methylprednisolone)	0	0	0	2	0	0	0	0	0	0	2
Know et al. (2009, polyethylene glycol)	0	0	0	2	0	0	0	0	0	0	2
Know et al. (2009, magnesium sulfate)	0	0	0	2	0	0	0	0	0	0	2

Know et al. (2009, magnesium sulfate + polyethylene glycol)	0	0	0	2	0	0	0	0	0	0	2
Know et al. (2009, magnesium chloride + polyethylene glycol)	0	0	0	2	0	0	0	0	0	0	2
Know et al. (2009, methylprednisolone + magnesium chloride + polyethylene glycol)	0	0	0	2	0	2	0	0	0	0	4
Kachadroka et al. (2010, estradiol)	0	0	0	0	0	0	0	0	0	0	0
Roman et al. (2011, polyethylene glycol)	0	0	0	0	0	0	0	0	1	1	2
Bu et al. (2018, estradiol)	0	0	2	0	0	0	2	0	1	1	6
Fakhri et al. (2020, melatonin)	0	0	0	1	0	0	0	0	0	0	1
Hook et al. (2009, morphine sulfate)	0	0	0	0	0	0	0	0	0	1	1
Garcia-Ovejero et al. (2014, progesterone)	0	0	0	0	0	0	0	0	0	1	1
Erol et al. (2016, methylprednisolone)	0	0	0	2	0	0	0	0	0	1	3
Erol et al. (2016, topiramate)	0	0	0	2	0	0	0	0	0	1	3
Streijger et al. (2016, magnesium chloride + polyethylene glycol)	0	0	0	2	0	0	0	0	0	1	3
Streijger et al. (2016, magnesium sulfate)	0	0	0	2	0	0	0	0	0	1	3
Ji et al. (2005, methylprednisolone)	0	1	0	0	0	0	0	0	0	1	2
Doyle et al. (2004, levodopa)	0	0	2	2	2	0	0	0	1	1	8
Ibarra et al. (2004, methylprednisolone sodium succinate)	0	2	0	0	0	0	0	0	0	0	2
Kuroiwa et al. (2014, amiloride)	0	1	0	0	0	0	0	0	0	0	1
Wells et al. (2003, methylprednisolone)	0	0	0	0	0	0	0	0	0	1	1
Wells et al. (2003, minocycline)	0	0	0	0	0	0	0	0	0	1	1
Guizar-Sahagun et al. (2009, methylprednisolone sodium succinate)	0	0	0	1	0	0	0	0	0	1	2
Guizar-Sahagun et al. (2009, melatonin)	0	0	0	1	0	0	0	0	0	1	2
Lee et al. (2010, minocycline)	0	0	2	2	0	0	0	0	0	0	4
Lee et al. (2010, simvastatin)	0	0	2	2	0	0	0	0	0	0	4
Zeman et al. (2009, oxandrolone)	0	1	0	1	0	0	0	0	0	0	2
Cole et al. (1989, fentanyl + nitrous oxide)	0	0	0	2	0	0	0	0	1	0	3
Cole et al. (1989, fentanyl + nitrous oxide + naloxone)	0	0	0	2	0	0	0	0	1	0	3
Kuchner et al. (2000, dexamethasone)	0	0	0	1	0	0	0	0	0	0	1
Luo et al. (2013, methylprednisolone)	0	0	0	0	0	0	0	0	0	1	1
Thomas et al. (1999, progesterone)	0	0	0	1	0	0	0	0	0	1	2
Stewart et al. (2019, folic acid)	0	0	0	0	0	0	0	0	0	0	0
Stewart et al. (2019, nitrous oxide)	0	0	0	0	0	0	0	0	0	0	0
Stewart et al. (2019, folic acid + nitrous oxide)	0	0	0	0	0	0	0	0	0	0	0
Gok et al. (2007, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Dinc et al. (2013, methylprednisolone)	0	0	0	2	0	0	2	0	1	1	6
Lee et al. (2010, magnesium)	0	0	0	2	0	0	0	0	0	1	3
Sonmez et al. (2013, minocycline)	0	0	0	1	0	0	0	0	0	1	2
Cuzzocrea et al. (2008, estradiol)	0	0	0	1	0	0	0	0	1	1	3
Ren et al. (2017, polyethylene glycol)	1	0	0	2	0	0	0	0	1	1	5
Faden et al. (1984, dexamethasone)	0	0	2	2	0	0	0	2	0	0	6
Faden et al. (1984, methylprednisolone)	0	0	2	2	0	0	0	0	0	0	4
Xu et al. (2019, melatonin)	0	2	2	2	0	0	0	0	1	0	7
Li et al. (2019, melatonin)	0	0	0	0	0	0	0	0	0	0	0
Yang et al. (2020, melatonin)	0	0	0	0	0	0	0	0	0	1	1
Piao et al. (2014, melatonin)	0	0	0	0	0	0	0	0	0	1	1
Zhang et al. (2019, melatonin)	0	0	0	1	0	0	0	0	0	0	1
Shen et al. (2017, melatonin)	0	1	0	1	0	0	2	0	0	0	4

Esposito et al. (2009, melatonin)	1	0	2	2	0	0	0	2	0	1	8
Jing et al. (2019, melatonin)	0	0	0	1	0	0	2	0	0	0	3
Fee et al. (2010, melatonin)	0	1	0	0	0	0	0	0	0	1	2
Jeffrey-Gauthier et al. (2018, buspirone)	0	0	0	2	0	0	0	0	0	1	3
Holtz et al. (1989, naloxone)	0	0	0	2	0	0	0	0	0	1	3
Park et al. (2012, melatonin)	0	0	0	0	0	0	0	0	0	0	0
Ates et al. (2006, methylprednisolone)	0	0	0	0	0	0	0	0	1	0	1
Ates et al. (2006, ethanol)	0	0	0	0	0	0	0	0	1	0	1
Yingli et al. (2014, melatonin)	0	0	0	1	0	0	2	0	0	1	4
Yune et al. (2007, minocycline)	0	0	0	1	0	0	0	0	0	0	1
Yune et al. (2007, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Zhang et al. (2017, metformin) - rats - 10.1111/jcmm.13235	0	1	0	1	0	0	0	0	0	0	2
Park et al. (2014, hydralazine)	0	1	0	2	0	0	0	0	0	1	4
Stirling et al. (2004, minocycline)	0	0	2	1	0	0	0	0	0	0	3
Weaver et al. (2005, methylprednisolone)	0	0	0	2	0	0	0	0	0	0	2
Moutaery et al. (2000, aluminum)	0	0	0	1	0	0	0	0	0	0	1
de Mesquita Coutinho et al. (2016, tacrolimus)	0	0	0	1	0	0	0	2	0	1	4
Takami et al. (2002, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Chikawa et al. (2001, methylprednisolone)	0	0	0	0	0	0	0	0	0	0	0
Aceves et al. (2019, morphine)	0	0	0	0	0	0	0	0	0	1	1
Aceves et al. (2019, minocycline)	0	0	0	0	0	0	0	0	0	1	1
Aceves et al. (2019, morphine + minocycline)	0	0	0	0	0	0	0	0	0	1	1
Woller et al. (2014, morphine)	0	0	0	0	0	0	0	0	0	1	1
de la Torre Valdovino et al. (2016, tamoxifen)	1	0	0	1	0	0	0	0	0	1	3
Guo et al. (2015, acetylcysteine)	0	1	0	1	0	0	0	0	1	1	4
Black et al. (1991, naloxone)	0	0	1	2	0	0	0	0	0	0	3
Black et al. (1986, naloxone) - rats - 10.1227/00006123-198612000-00004	0	0	0	0	0	0	0	0	0	0	0
Black et al. (1986, naloxone) - rats - 10.1227/00006123-198612000-00005	0	0	0	2	0	0	0	0	0	0	2
Wang et al. (2020, metformin)	0	0	0	2	0	0	0	0	1	0	3
Lin et al. (2019, methylprednisolone)	0	1	0	0	0	2	0	0	1	0	4
Lin et al. (2019, methylprednisolone sodium succinate)	0	1	0	0	0	2	0	0	1	0	4
Koyanagi, Tator (1997, methylprednisolone)	0	0	0	2	0	0	0	0	0	1	3
Hook et al. (2017, morphine)	0	0	0	0	0	0	0	0	0	1	1
Wu et al. (2016, botulinum toxin)	0	0	0	1	0	0	0	0	1	0	2
Guth et al. (1994, indomethacin)	0	0	0	2	0	0	2	0	0	0	4
Lee et al. (2012, fluoxetine)	0	1	0	1	0	0	0	0	0	0	2
Gao et al. (2020, melatonin)	0	0	0	2	0	0	0	0	0	0	2
Gorio et al. (2005, methylprednisolone sodium succinate)	0	1	2	1	0	0	2	0	0	0	6
Scali et al. (2013, fluoxetine)	0	1	0	0	0	0	0	0	0	1	2
Dixit et al. (2018, clonidine)	0	0	0	1	0	0	0	0	0	1	2
Zhang et al. (2014, methylprednisolone sodium succinate)	0	0	2	2	0	2	2	2	1	1	12
Nazli et al. (2015, atorvastatin)	0	0	2	2	1	0	0	0	0	0	5
Li et al. (2014, atorvastatin)	0	0	0	1	0	0	0	0	0	1	2
Bharne et al. (2013, methylprednisolone)	0	0	0	1	0	0	0	0	0	1	2
Cayli et al. (2006, etomidate + methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Cong, Chen (2016, dexamethasone)	0	0	0	1	0	0	0	0	0	0	1

Tan et al. (2015, methylprednisolone)	0	0	0	1	0	0	0	0	0	1	2
Cakir et al. (2003, acetylcysteine)	0	0	2	2	1	0	0	2	0	1	8
Gao et al. (2015, simvastatin)	0	0	0	1	0	0	0	0	0	0	1
Hou et al. (2016, methylprednisolone)	0	0	0	0	0	0	0	0	0	1	1
Wang et al. (2014, methylprednisolone)	0	1	0	0	0	0	0	0	0	0	1
Sozbilen et al. (2018, methylprednisolone)	0	0	0	1	0	0	0	0	0	1	2
Yilmaz et al. (2015, clopidogrel)	0	0	0	2	0	0	0	0	0	0	2
Chen et al. (2015, methylprednisolone)	0	2	0	2	0	0	0	0	0	0	4
Ok et al. (2012, methylprednisolone)	0	0	0	1	0	0	0	0	1	0	2
Kazanci et al. (2017, methylprednisolone + pregabalin)	0	0	2	1	1	0	0	0	0	1	5
Kahveci et al. (2014, methylprednisolone + rosuvastatin)	0	0	0	1	0	0	0	0	0	0	1
Xian-Hui et al. (2016, methylprednisolone)	0	0	0	1	0	1	0	2	0	0	4
Kouhzaei et al. (2013, polyethylene glycol)	0	1	0	1	0	0	0	0	0	1	3
Aceves et al. (2016, morphine)	0	0	0	0	0	0	0	0	0	1	1
Guizar-Sahagun et al. (2005, methylprednisolone sodium succinate)	0	0	0	1	0	0	0	0	0	1	2
De La Torre et al. (1975, mannitol)	0	0	0	2	0	0	0	0	1	1	4
De La Torre et al. (1975, dexamethasone)	0	0	0	2	0	0	0	0	1	1	4
Yates et al. (2014, methylprednisolone)	0	1	0	2	0	0	0	0	0	1	4
Flamm et al. (1982, naloxone)	0	0	2	2	0	0	0	0	1	1	6
Wallace, Tator (1986, naloxone) - rats - 10.1227/00006123-198604000-00006	0	0	0	2	0	0	0	0	0	1	3
Wallace, Tator (1986, naloxone) - rats - 10.1227/00006123-198610000-00001	0	0	0	2	0	0	0	0	0	1	3
Cho et al. (2010, glucosamine)	0	0	0	1	1	2	0	0	0	1	5
Zadeh-Ardabili et al. (2017, vitamin e)	0	0	0	0	0	0	2	0	0	1	3
Gok et al. (2009, albumin)	0	0	0	1	0	0	0	0	0	0	1
Gok et al. (2009, immune globulin)	0	0	0	1	0	0	0	0	0	0	1
Khajouejinejad et al. (2019, calcitriol)	0	0	0	0	0	0	0	0	0	0	0
Lim et al. (2013, omega 3)	0	0	0	2	0	0	0	0	0	0	2
Popovich et al. (2012, glibenclamide)	0	1	0	0	0	0	0	0	0	0	1
Pukos, McTigue (2020, tamoxifen)	0	0	0	0	0	0	0	0	0	0	0
Durham-Lee et al. (2012, amiloride)	0	1	0	2	0	0	0	0	0	1	4
Perez-Espejo et al. (1996, methylprednisolone)	0	0	0	2	0	0	0	0	1	0	3
Patel et al. (2017, pioglitazone)	0	0	0	2	0	0	0	0	0	1	3
Nash et al. (2002, methylprednisolone)	0	0	2	1	0	0	0	0	0	1	4
Lankhorst et al. (2000, methylprednisolone)	0	0	0	0	0	0	0	0	0	0	0
Liu et al. (2010, carbidopa levodopa)	0	0	0	1	0	0	2	0	0	1	4
Yang et al. (2020, glutamine)	0	0	0	0	0	0	0	0	0	0	0
Pannu et al. (2007, atorvastatin)	0	0	0	2	0	0	0	0	0	0	2
Mann et al. (2010, atorvastatin)	0	0	0	2	0	0	0	0	0	0	2
Mann et al. (2010, simvastatin)	0	0	0	2	0	0	0	0	0	0	2
King et al. (2006, omega 3) - rats - 10.1523/JNEUROSCI.5539-05.2006 - alpha-linolenic acid (AHA)	0	0	0	1	0	0	0	0	0	1	2
King et al. (2006, omega 3) - rats - 10.1523/JNEUROSCI.5539-05.2006 - docosahexaenoic acid (DHA)	0	0	0	1	2	0	0	0	0	1	4
Fujimoto et al. (2000, melatonin)	0	0	0	2	0	0	0	0	0	0	2
Schiaveto-de-Souza et al. (2013, melatonin)	0	0	0	2	0	0	0	0	0	1	3
Karami et al. (2013, ketoprofen)	0	0	0	2	0	0	0	0	0	1	3
Tan et al. (2020, estrogen)	0	0	0	0	0	0	0	0	0	0	0

Wang et al. (2015, propofol)	0	0	0	0	0	0	0	0	0	1	1
Zhang et al. (2020, mannitol)	0	0	0	0	0	0	0	0	0	0	0
Yates et al. (2009, modafinil)	0	0	0	1	0	0	0	0	0	1	2
Iwasa et al. (1989, vitamin e)	0	0	0	2	0	0	0	0	0	1	3
Sengelaub et al. (2018, estradiol)	0	0	0	1	0	0	0	0	0	0	1
Sengelaub et al. (2018, testosterone)	0	0	0	1	0	0	0	0	0	0	1
Sengelaub et al. (2018, estradiol + testosterone)	0	0	0	1	0	0	0	0	0	0	1
Patel et al. (2014, acetylcysteine)	0	0	0	2	0	0	0	0	0	1	3
Osuna-Carrasco et al. (2016, tamoxifen)	0	0	0	1	0	0	0	0	0	1	2
Ren et al. (2019, polyethylene glycol)	0	0	0	2	0	0	0	0	0	1	3
Kaptanoglu et al. (2005, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Kaptanoglu et al. (2005, mexiletine)	0	0	0	1	0	0	0	0	0	0	1
Xing et al (2016, morphine)	0	0	0	1	0	0	0	0	0	0	1
Mu et al (2000, methylprednisolone)	0	0	0	1	0	0	0	0	0	0	1
Kazama et al (2001, pentobarbital)	0	0	2	2	1	0	0	0	0	0	5
Genovese et al (2007, dexamethasone)	0	2	0	1	0	0	0	0	0	1	4
Pan et al (2013, tacrolimus)	0	0	0	1	0	0	0	0	0	0	1
Pereira et al (2009, methylprednisolone sodium succinate)	0	0	0	1	0	0	0	0	0	1	2
Cain et al (2007, albumin)	0	0	0	2	0	0	0	0	0	0	2
Liang et al (2019, simvastatin)	0	0	0	0	0	0	0	0	0	1	1
Liang et al (2019, ezetimibe + simvastatin)	0	0	0	0	0	0	0	0	0	1	1
Gao et al (2016, simvastatin)	0	1	0	1	0	0	0	0	0	0	2
Han et al (2012, simvastatin)	0	0	0	2	0	0	0	0	0	0	2
Han et al (2011, simvastatin)	0	0	0	1	0	0	0	0	0	1	2
Han et al (2020, sitagliptin)	0	1	0	0	0	0	0	0	1	0	2
He et al (2016, propofol)	0	0	0	0	0	0	0	0	0	1	1
Holmberg et al (2008, simvastatin)	0	1	0	1	0	1	2	0	0	1	6
Zhang et al (2018, lithium)	0	0	0	1	0	0	0	0	0	0	1
Tedeschi et al (2016, pregabalin)	0	1	0	0	0	0	0	0	0	1	2
Kim et al (2017, lithium)	0	0	0	0	0	0	0	0	0	0	0
Sanli et al (2012, methylprednisolone sodium succinate)	0	0	0	1	0	0	0	0	0	0	1
Salimi et al (2020, ceftriaxone)	0	0	0	0	0	0	2	0	0	0	2
Salimi et al (2020, acetylcysteine)	0	0	0	0	0	0	2	0	0	0	2
Salimi et al (2020, ceftriaxone + acetylcysteine)	0	0	0	0	0	0	2	0	0	0	2
Ni et al (2018, estrogen)	0	1	0	1	0	0	0	0	0	0	2
Xiao Jianru et al (1998, naloxone)	0	0	0	2	0	0	0	2	0	1	5
Baffour et al (1995, methylprednisolone sodium succinate)	0	0	1	2	0	0	0	0	1	0	4
Qi et al (2017, methylprednisolone)	0	0	0	0	0	0	0	0	0	1	1
Yune et al (2004, estradiol)	0	1	0	1	0	0	0	0	0	0	2
Nacar et al (2014, polyethylene glycol)	0	0	0	2	0	0	0	0	1	0	3
Nacar et al (2014, atorvastatin)	0	0	0	2	0	0	0	0	0	0	2
Baptiste et al (2009, polyethylene glycol)	0	0	0	1	0	0	0	0	0	0	1
Mallei et al (2005, prednisolone)	0	1	0	1	0	0	0	0	0	0	2
Madsen et al (1998, tacrolimus)	0	1	2	2	0	0	0	0	0	0	5
Colón et al (2016, tamoxifen)	0	0	0	1	0	0	0	0	0	0	1
Mosquera et al (2014, estradiol)	0	1	0	1	0	0	0	0	0	0	2

Mosquera et al (2014, tamoxifen)	0	1	0	1	0	0	0	0	0	0	2
Tian et al (2009, tamoxifen)	0	0	0	1	0	0	0	0	0	0	1
Kitchen et al (2020, trifluoperazine)	0	1	0	0	0	0	0	0	0	0	1
Namjoo et al (2018, estradiol) - rats - 10.1002/jcb.27361	0	0	0	1	0	0	0	0	0	1	2
Borgens et al (2002, polyethylene glycol)	1	0	2	1	0	0	0	0	0	0	4
Hao et al (1991, naltrexone)	0	0	0	2	0	0	0	0	0	1	3
Ruhollah Hosseini et al (2017, dexamethasone)	0	0	0	1	0	0	0	0	0	1	2
Pedram et al (2018, meloxicam)	0	0	0	0	0	0	0	0	0	0	0
Sharma et al (2004, methylprednisolone sodium succinate)	0	0	1	2	1	0	0	2	1	1	8
Sharma et al (2004, dexamethasone)	0	0	1	2	1	0	0	2	1	1	8
Guptarak et al (2014, tamoxifen)	0	0	0	2	0	0	0	0	0	0	2
Kermani et al (2016, acetylsalicylic acid)	0	0	0	1	0	0	0	0	0	0	1
Sayin et al (2013, methylprednisolone sodium succinate)	0	0	0	1	0	0	0	0	0	0	1
Baysefer et al (2003, mannitol)	0	0	0	2	0	0	0	0	0	1	3
Farooque et al (1994, methylprednisolone sodium succinate)	0	0	0	2	0	0	0	0	0	1	3
Golding et al (2006, glutamine)	0	0	0	0	0	0	0	0	0	1	1
Abdanipour et al (2019, lithium)	1	0	0	0	0	0	0	0	0	1	2
Charn et al (2011, minocycline)	0	0	0	2	0	0	0	0	0	0	2
Gul et al (2010, methylprednisolone)	0	0	0	1	0	0	0	0	2	1	4
Gul et al (2010, dexmedetomidine)	0	0	0	1	0	0	0	0	2	1	4
Lang-Lazdunski et al (2001, tacrolimus)	0	0	0	2	1	0	0	0	0	1	4
Rosado et al (2014, methylprednisolone sodium succinate)	0	0	0	0	0	0	0	0	0	0	0
Rosado et al (2014, dantrolene)	0	0	0	0	0	0	0	0	0	0	0
Rosado et al (2014, methylprednisolone sodium succinate + dantrolene)	0	0	0	0	0	0	0	0	0	0	0
Boran et al (2005, methylprednisolone)	0	0	0	2	0	0	0	0	0	0	2
Boran et al (2005, epoetin)	0	0	0	2	0	0	0	0	0	0	2
Hook et al (2007, morphine sulfate)	0	0	0	0	0	0	0	0	0	0	0
Simpson et al (1991, nifedipine)	0	0	2	2	1	0	0	0	0	1	6
Simpson et al (1991, indomethacin)	0	0	2	2	1	0	0	0	0	1	6
He et al (2017, lithium)	0	1	0	1	0	0	0	0	1	1	4
Almad et al (2011, fenofibrate)	0	1	0	1	0	0	0	0	0	0	2
McTigue et al (2007, pioglitazone)	0	0	0	1	0	0	0	0	0	0	1
Ko et al (2006, minocycline)	0	0	2	0	0	0	0	0	0	0	2
Çelik et al (2015, vitamin d)	0	0	2	2	0	0	0	0	1	1	6
Park et al (2007, pioglitazone)	0	1	2	1	0	0	0	0	0	0	4
Afhami et al (2016, estradiol)	0	0	0	1	0	0	0	0	0	1	2
Gezici et al (2017, methotrexate)	0	0	0	1	0	0	0	0	0	0	1
Narin et al (2017, topiramate)	0	0	0	0	0	0	0	0	0	0	0
Gensel et al (2012, topiramate)	0	0	0	0	0	0	0	0	0	1	1
Yoshizaki et al (2019, heparin)	0	0	0	0	0	0	0	0	0	0	0
Arias (1987, naloxone)	0	1	0	2	0	0	0	0	1	1	5
Arias (1987, dexamethasone)	0	1	0	2	0	0	0	0	1	1	5
Naftchi et al (1991, methylprednisolone sodium succinate + aminocaproic acid)	0	0	2	2	0	0	0	0	2	1	7
Romero-Ramírez et al (2020, methylprednisolone)	0	0	0	0	0	0	0	0	1	1	2
Zhang et al (2009, tacrolimus)	0	0	0	2	0	0	0	0	0	1	3
Zhang et al (2014, methylprednisolone)	0	0	2	0	0	0	0	0	0	0	2

Rabinowitz et al (2008, methylprednisolone)	0	0	0	1	0	0	0	0	0	1	2
Penas et al (2011, valproic acid)	0	0	0	0	0	0	0	0	1	0	1
Chu et al (2015, valproic acid)	0	0	0	1	0	0	0	0	0	0	1
Lee et al (2012, valproic acid)	0	1	0	1	0	0	0	0	0	0	2
Lu et al (2013, valproic acid)	0	0	0	1	0	0	0	0	0	0	1
Lv et al (2012, valproic acid)	0	1	0	2	0	0	0	0	0	0	3
Lv et al (2011, valproic acid)	0	1	0	2	0	0	0	0	0	0	3
Hao et al (2013, valproic acid)	0	1	0	1	0	0	0	0	0	0	2
Wang et al (2020, valproic acid)	0	0	0	1	0	0	0	0	0	1	2
Li et al (2019, zinc)	0	0	0	1	0	0	0	0	0	1	2
Lin et al (2020, zinc) - mice - 10.1016/j.neulet.2020.135263	0	1	0	0	0	0	2	0	0	0	3
Li et al (2020, zinc)	0	1	0	0	0	0	0	0	0	0	1
Lin et al (2020, zinc) - mice - 10.1111/cns.13460	0	1	0	0	0	0	0	0	0	0	1